Novartis India has acquired the trademarks for hypertension drug 'Minipress' from Pfizer for ₹1,250 crore and secured distribution rights for retinal treatments. These moves mark the company’s first major expansion since private equity firm ChrysCapital took control in July 2026, signaling a shift toward owning and managing its own branded portfolio.
Novartis India is rapidly changing its business model following a leadership transition. On September 8, 2026, the company announced two key deals to expand its product portfolio. The most significant move is the acquisition of trademarks and intellectual property for 'Minipress' and 'Minipres' from Pfizer for ₹1,250 crore. This asset, used for treating hypertension and benign prostatic hyperplasia, provides the company with a stable, established brand that was previously marketed by Pfizer.
Simultaneously, the company entered into an exclusive promotion and distribution agreement with Novartis Healthcare Private Limited (NHPL), the Indian unit of the Swiss pharmaceutical major. This agreement, which involves an upfront payment of ₹10 crore, gives Novartis India the rights to market retinal therapies like Accentrix and Pagenax. This entry into the ophthalmology segment is a strategic addition, as it moves the company beyond its traditional legacy brands.
These actions follow the July 2026 acquisition of a 70.68% stake in Novartis India by private equity firm ChrysCapital for ₹1,446 crore. Before this change in ownership, the company operated primarily as a distributor of generic brands manufactured by its Swiss parent. Under the new management, the company is shifting toward a model of owning its own assets and independently driving growth in specialized therapy areas.
For investors, these deals represent a departure from the company’s conservative past. By acquiring intellectual property, the company aims to move toward higher margins and tighter control over its product lifecycle. However, this strategy comes with its own set of challenges. Integrating these new assets into the existing business requires effective operational management. Investors should monitor how the company handles the transition, especially given that the acquired hypertension brand has previously seen growth rates that lagged behind its wider market category.
Another point of focus will be the company’s ability to compete in the broader Indian pharmaceutical sector. The industry is highly competitive, and relying on a new, branded portfolio requires strong execution in sales and marketing. The company currently maintains a debt-free balance sheet, which provides some flexibility for these capital investments. Going forward, the primary monitorables include the company's ability to maintain profit margins amid the integration process and its performance in these new therapeutic categories compared to established industry peers.